Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer

Sagar R. Shah, Jayoung Kim, Paula Schiapparelli, Carla A. Vazquez-Ramos, Juan C. Martinez-Gutierrez, Alejandro Ruiz-Valls, Kyle Inman, James G. Shamul, Jordan J. Green, Alfredo Quinones-Hinojosa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Glioblastoma (GBMs) is the most common and aggressive type of primary brain tumor in adults with dismal prognosis despite radical surgical resection coupled with chemo- and radiotherapy. Recent studies have proposed the use of small-molecule inhibitors, including verteporfin (VP), to target oncogenic networks in cancers. Here we report efficient encapsulation of water-insoluble VP in poly(lactic-co-glycolic acid) microparticles (PLGA MP) of ∼1.5 μm in diameter that allows tunable, sustained release. Treatment with naked VP and released VP from PLGA MP decreased cell viability of patient-derived primary GBM cells in vitro by ∼70%. Moreover, naked VP treatment significantly increased radiosensitivity of GBM cells, thereby enhancing overall tumor cell killing ability by nearly 85%. Our in vivo study demonstrated that two intratumoral administrations of sustained slow-releasing VP-loaded PLGA MPs separated by two weeks significantly attenuated tumor growth by ∼67% in tumor volume in a subcutaneous patient-derived GBM xenograft model over 26 d. Additionally, our in vitro data indicate broader utility of VP for treatment for other solid cancers, including chordoma, malignant meningioma, and various noncentral nervous system-derived carcinomas. Collectively, our work suggests that the use of VP-loaded PLGA MP may be an effective local therapeutic strategy for a variety of solid cancers, including unresectable and orphan tumors, which may decrease tumor burden and ultimately improve patient prognosis.

Original languageEnglish (US)
Pages (from-to)1433-1443
Number of pages11
JournalMolecular Pharmaceutics
Volume16
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Brain Neoplasms
Glioblastoma
Neoplasms
Therapeutics
Tumor Burden
Chordoma
Orphaned Children
verteporfin
Radiation Tolerance
Meningioma
Heterografts
Nervous System
Cell Survival
Radiotherapy
Carcinoma
Drug Therapy
polylactic acid-polyglycolic acid copolymer
Water
Growth

Keywords

  • brain cancer
  • cancer therapy
  • chordoma
  • glioblastoma
  • intratumoral treatment
  • local delivery
  • malignant meningioma
  • microparticles
  • microspheres
  • PLGA
  • poly(lactic- co-glycolic acid)
  • radiosensitization
  • verteporfin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Shah, S. R., Kim, J., Schiapparelli, P., Vazquez-Ramos, C. A., Martinez-Gutierrez, J. C., Ruiz-Valls, A., ... Quinones-Hinojosa, A. (2019). Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer. Molecular Pharmaceutics, 16(4), 1433-1443. https://doi.org/10.1021/acs.molpharmaceut.8b00959

Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer. / Shah, Sagar R.; Kim, Jayoung; Schiapparelli, Paula; Vazquez-Ramos, Carla A.; Martinez-Gutierrez, Juan C.; Ruiz-Valls, Alejandro; Inman, Kyle; Shamul, James G.; Green, Jordan J.; Quinones-Hinojosa, Alfredo.

In: Molecular Pharmaceutics, Vol. 16, No. 4, 01.04.2019, p. 1433-1443.

Research output: Contribution to journalArticle

Shah, SR, Kim, J, Schiapparelli, P, Vazquez-Ramos, CA, Martinez-Gutierrez, JC, Ruiz-Valls, A, Inman, K, Shamul, JG, Green, JJ & Quinones-Hinojosa, A 2019, 'Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer', Molecular Pharmaceutics, vol. 16, no. 4, pp. 1433-1443. https://doi.org/10.1021/acs.molpharmaceut.8b00959
Shah SR, Kim J, Schiapparelli P, Vazquez-Ramos CA, Martinez-Gutierrez JC, Ruiz-Valls A et al. Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer. Molecular Pharmaceutics. 2019 Apr 1;16(4):1433-1443. https://doi.org/10.1021/acs.molpharmaceut.8b00959
Shah, Sagar R. ; Kim, Jayoung ; Schiapparelli, Paula ; Vazquez-Ramos, Carla A. ; Martinez-Gutierrez, Juan C. ; Ruiz-Valls, Alejandro ; Inman, Kyle ; Shamul, James G. ; Green, Jordan J. ; Quinones-Hinojosa, Alfredo. / Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer. In: Molecular Pharmaceutics. 2019 ; Vol. 16, No. 4. pp. 1433-1443.
@article{728e3ab434de41458533d0cf83b933e7,
title = "Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer",
abstract = "Glioblastoma (GBMs) is the most common and aggressive type of primary brain tumor in adults with dismal prognosis despite radical surgical resection coupled with chemo- and radiotherapy. Recent studies have proposed the use of small-molecule inhibitors, including verteporfin (VP), to target oncogenic networks in cancers. Here we report efficient encapsulation of water-insoluble VP in poly(lactic-co-glycolic acid) microparticles (PLGA MP) of ∼1.5 μm in diameter that allows tunable, sustained release. Treatment with naked VP and released VP from PLGA MP decreased cell viability of patient-derived primary GBM cells in vitro by ∼70{\%}. Moreover, naked VP treatment significantly increased radiosensitivity of GBM cells, thereby enhancing overall tumor cell killing ability by nearly 85{\%}. Our in vivo study demonstrated that two intratumoral administrations of sustained slow-releasing VP-loaded PLGA MPs separated by two weeks significantly attenuated tumor growth by ∼67{\%} in tumor volume in a subcutaneous patient-derived GBM xenograft model over 26 d. Additionally, our in vitro data indicate broader utility of VP for treatment for other solid cancers, including chordoma, malignant meningioma, and various noncentral nervous system-derived carcinomas. Collectively, our work suggests that the use of VP-loaded PLGA MP may be an effective local therapeutic strategy for a variety of solid cancers, including unresectable and orphan tumors, which may decrease tumor burden and ultimately improve patient prognosis.",
keywords = "brain cancer, cancer therapy, chordoma, glioblastoma, intratumoral treatment, local delivery, malignant meningioma, microparticles, microspheres, PLGA, poly(lactic- co-glycolic acid), radiosensitization, verteporfin",
author = "Shah, {Sagar R.} and Jayoung Kim and Paula Schiapparelli and Vazquez-Ramos, {Carla A.} and Martinez-Gutierrez, {Juan C.} and Alejandro Ruiz-Valls and Kyle Inman and Shamul, {James G.} and Green, {Jordan J.} and Alfredo Quinones-Hinojosa",
year = "2019",
month = "4",
day = "1",
doi = "10.1021/acs.molpharmaceut.8b00959",
language = "English (US)",
volume = "16",
pages = "1433--1443",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer

AU - Shah, Sagar R.

AU - Kim, Jayoung

AU - Schiapparelli, Paula

AU - Vazquez-Ramos, Carla A.

AU - Martinez-Gutierrez, Juan C.

AU - Ruiz-Valls, Alejandro

AU - Inman, Kyle

AU - Shamul, James G.

AU - Green, Jordan J.

AU - Quinones-Hinojosa, Alfredo

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Glioblastoma (GBMs) is the most common and aggressive type of primary brain tumor in adults with dismal prognosis despite radical surgical resection coupled with chemo- and radiotherapy. Recent studies have proposed the use of small-molecule inhibitors, including verteporfin (VP), to target oncogenic networks in cancers. Here we report efficient encapsulation of water-insoluble VP in poly(lactic-co-glycolic acid) microparticles (PLGA MP) of ∼1.5 μm in diameter that allows tunable, sustained release. Treatment with naked VP and released VP from PLGA MP decreased cell viability of patient-derived primary GBM cells in vitro by ∼70%. Moreover, naked VP treatment significantly increased radiosensitivity of GBM cells, thereby enhancing overall tumor cell killing ability by nearly 85%. Our in vivo study demonstrated that two intratumoral administrations of sustained slow-releasing VP-loaded PLGA MPs separated by two weeks significantly attenuated tumor growth by ∼67% in tumor volume in a subcutaneous patient-derived GBM xenograft model over 26 d. Additionally, our in vitro data indicate broader utility of VP for treatment for other solid cancers, including chordoma, malignant meningioma, and various noncentral nervous system-derived carcinomas. Collectively, our work suggests that the use of VP-loaded PLGA MP may be an effective local therapeutic strategy for a variety of solid cancers, including unresectable and orphan tumors, which may decrease tumor burden and ultimately improve patient prognosis.

AB - Glioblastoma (GBMs) is the most common and aggressive type of primary brain tumor in adults with dismal prognosis despite radical surgical resection coupled with chemo- and radiotherapy. Recent studies have proposed the use of small-molecule inhibitors, including verteporfin (VP), to target oncogenic networks in cancers. Here we report efficient encapsulation of water-insoluble VP in poly(lactic-co-glycolic acid) microparticles (PLGA MP) of ∼1.5 μm in diameter that allows tunable, sustained release. Treatment with naked VP and released VP from PLGA MP decreased cell viability of patient-derived primary GBM cells in vitro by ∼70%. Moreover, naked VP treatment significantly increased radiosensitivity of GBM cells, thereby enhancing overall tumor cell killing ability by nearly 85%. Our in vivo study demonstrated that two intratumoral administrations of sustained slow-releasing VP-loaded PLGA MPs separated by two weeks significantly attenuated tumor growth by ∼67% in tumor volume in a subcutaneous patient-derived GBM xenograft model over 26 d. Additionally, our in vitro data indicate broader utility of VP for treatment for other solid cancers, including chordoma, malignant meningioma, and various noncentral nervous system-derived carcinomas. Collectively, our work suggests that the use of VP-loaded PLGA MP may be an effective local therapeutic strategy for a variety of solid cancers, including unresectable and orphan tumors, which may decrease tumor burden and ultimately improve patient prognosis.

KW - brain cancer

KW - cancer therapy

KW - chordoma

KW - glioblastoma

KW - intratumoral treatment

KW - local delivery

KW - malignant meningioma

KW - microparticles

KW - microspheres

KW - PLGA

KW - poly(lactic- co-glycolic acid)

KW - radiosensitization

KW - verteporfin

UR - http://www.scopus.com/inward/record.url?scp=85063124135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063124135&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.8b00959

DO - 10.1021/acs.molpharmaceut.8b00959

M3 - Article

VL - 16

SP - 1433

EP - 1443

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 4

ER -